Bahrain Pharmaceuticals and Healthcare Report Q4 2009
Business Monitor International, October 2009, Pages: 75
Bahrain Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Bahrain's pharmaceuticals and healthcare industry.
From BHD44mn (US$114mn) in 2008, BMI forecasts that Bahrain’s pharmaceutical market will expand to be worth BHD61mn (US$160mn) in 2018. While the market will remain small in absolute terms, rapid value growth, representing a compound annual growth rate (CAGR) of 6.8% and a favourable political economic and business environment mean that the country is likely to increasingly feature in drugmakers’ Middle East and Africa (MEA) strategies.
In BMI’s Q409 Business Environment Rating for the 17 countries of the MEA region, Bahrain ranks eighth. The potential returns from the market are constrained by the island’s population of just 1mn. However, a strong regulatory structure and stable political climate create a relatively low-risk business environment.
The Gulf Co-operation Council (GCC) member states already work together on a number of regulatory fronts and hope to deepen this collaboration in the coming years. At present, the GCC operates a unified import tariff system, as well as a system of collective tenders for group purchasing of drugs and vaccines. These tenders are an important way for multinational drugmakers to supply the Bahraini market. Healthcare is provided free of charge by the government to all citizens of Bahrain. Although, along with a number of other Gulf states, Bahrain has recently excluded non-Bahrain nationals from the public healthcare system. As a result, expatriates have to purchase private insurance – either personally or through their employers – or pay out-of-pocket for their treatments.
Demand for healthcare is growing rapidly due to a combination of factors including population growth, an ageing population, and a higher prevalence of chronic disease. According to a Ministry of Health study published in 2008, these three factors alone will cause healthcare expenditure to increase by around 500% over the next 20 years to reach BHD1.15mn in 2025, assuming no changes in the type of care provided. Private healthcare is likely to see considerable growth over the coming years. The artificial ‘health island’ known as Dilmunia, off the north coast of Bahrain should become a focal point for the growing private healthcare industry in the country and provide a major draw for health tourists from overseas. The project is progressing on schedule, with land reclamation work completed at the beginning of June 2009. The first phase of the project is expected to be completed in 2012, and the second phase in 2015.
Executive Summary
SWOT Analysis
- Bahrain Pharmaceuticals And Healthcare Industry SWOT
- Bahrain Political SWOT
- Bahrain Economic SWOT
- Bahrain Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Middle East And Africa Pharmaceutical Business Environment Ratings for Q409
- Limits of Potential Returns
- Risks to Realisation of Returns
Bahrain – Market Summary
Regulatory Regime
- Recent Regulatory Developments
- GCC Healthcare Collaboration
- Intellectual Property Developments
- Pricing and Reimbursement Regime
- Regional Price Harmonisation
- Free Trade Agreement with the US
- Other Free Trade Agreements
Industry Developments
- Epidemiology
- Table: Leading Causes Of Death In Bahrain, 2002
- HIV/AIDS
- Healthcare Sector
- Primary, Secondary and Tertiary Healthcare
- Health Insurance
- Table: National Health Insurance Scheme Breakdown
- Strategic Healthcare Goals
- Healthcare Sector Investment
- Features Of Dilmunia Health Island
- Pharmaceutical Sector
- Pharmaceutical Retail
- Research and Development
- International Collaboration
- Medical Devices
Industry Forecast Scenario
- Overall Market Forecast
- Table: Bahrain - Drug Expenditure Indicators, Historical Data and Forecasts
- Key Growth Factors – Industry
- Table: Bahrain - Health Expenditure Indicators, Historical Data and Forecasts
- Key Growth Factors – Macroeconomic
- Table: Bahrain – Economic Activity, 2006-2013
- Prescription Market Forecast
- Table: Bahrain – Prescription Market Indicators, Historical Data and Forecasts (US$mn unless otherwise indicated)
- Patented Market Forecast
- Table: Bahrain – Prescription Drug Market Indicators, Historical Data and Forecasts
- Generics Drug Market Forecast
- Table: Bahrain – Generics Drug Market Indicators, Historical Data and Forecasts
- OTC Market Forecast
- Table: Bahrain - OTC Market Indicators, Historical Data and Forecasts (US$mn unless otherwise stated)
- Pharmaceutical Trade Forecast
- Table: Bahrain – Pharmaceutical Trade Balance Indicators, Historical Data and Forecasts (US$mn)
- Medical Devices
- Table: Bahrain – Medical Device Market Indicators, Historical Data and Forecasts
- Other Healthcare Data Forecasts
- Table: Bahrain – Other Health Indicators, Historical Data and Forecasts, 2003-2013
- Key Risks to BMI’s Forecast Scenario
Competitive Landscape
Company Monitor
- Multinational Companies
- Novartis
- Johnson & Johnson (J&J)
- Merck & Co
- Pfizer
- GlaxoSmithKline
- GlaxoSmithKline
- Indigenous Companies
- Bahrain Industrial Pharmaceutical Co (Bidapharm)
- Al-Jishi Corporation
- Behzad Medical Establishment
- Yousuf Mahmood Husain Company
Country Snapshot: Bahrain Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education and Healthcare
- Table: Education
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market and Spending Power
- Table: Employment Indicators
- Table: Consumer Expenditure, 1999-2004 (US$)
- Table: Average Annual Wages
BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceutical Business Environment Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources
- Novartis
- Johnson & Johnson (J&J)
- Merck & Co
- Pfizer
- GlaxoSmithKline
- Bahrain Industrial Pharmaceutical Co (Bidapharm)
- Al-Jishi Corporation
- Behzad Medical Establishment
- Yousuf Mahmood Husain Company
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
